News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
750,648 Results
Type
Article (48409)
Company Profile (318)
Press Release (701899)
Multimedia
Podcasts (111)
Webinars (23)
Section
Business (209909)
Career Advice (2214)
Deals (36177)
Drug Delivery (146)
Drug Development (82807)
Employer Resources (197)
FDA (16670)
Job Trends (15373)
News (354218)
Policy (33480)
Tag
2027 BioCapital Elite (1)
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (4)
Academia (2782)
Academic (2)
Accelerated approval (43)
Adcomms (28)
Allergies (167)
Alliances (51150)
ALS (201)
Alzheimer's disease (1811)
Antibody-drug conjugate (ADC) (425)
Approvals (17000)
Artificial intelligence (660)
Autoimmune disease (247)
Automation (53)
Bankruptcy (368)
Best Places to Work (11826)
BIOSECURE Act (21)
Biosimilars (212)
Biotechnology (198)
Bladder cancer (183)
Brain cancer (68)
Breast cancer (714)
Cancer (5606)
Cardiovascular disease (461)
Career advice (1884)
Career pathing (46)
CAR-T (323)
CDC (61)
Celiac Disease (2)
Cell therapy (850)
Cervical cancer (44)
Clinical research (71210)
Collaboration (2049)
Company closure (4)
Compensation (1320)
Complete response letters (77)
COVID-19 (2813)
CRISPR (104)
C-suite (1076)
Cystic fibrosis (150)
Data (7413)
Decentralized trials (3)
Denatured (42)
Depression (159)
Dermatology (70)
Diabetes (559)
Diagnostics (7033)
Digital health (53)
Diversity (13)
Diversity, equity & inclusion (48)
Drug discovery (323)
Drug pricing (206)
Drug shortages (32)
Duchenne muscular dystrophy (274)
Earnings (92111)
Editorial (67)
Employer branding (25)
Employer resources (167)
Events (122449)
Executive appointments (1084)
FDA (20233)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (14)
Frontotemporal dementia (33)
Funding (1713)
Gene editing (225)
Generative AI (59)
Gene therapy (689)
GLP-1 (1077)
Government (4880)
Grass and pollen (6)
Guidances (402)
Healthcare (19346)
HIV (77)
Huntington's disease (55)
IgA nephropathy (95)
Immunology and inflammation (285)
Immuno-oncology (86)
Indications (166)
Infectious disease (3147)
Inflammatory bowel disease (212)
Inflation Reduction Act (16)
Influenza (134)
Intellectual property (282)
Interviews (350)
IPO (16869)
IRA (52)
Job creations (3858)
Job search strategy (1579)
JPM (62)
Kidney cancer (18)
Labor market (103)
Layoffs (584)
Leadership (39)
Legal (8114)
Liver cancer (99)
Longevity (30)
Lung cancer (753)
Lymphoma (418)
Machine learning (57)
Management (63)
Manufacturing (983)
MASH (182)
Medical device (14040)
Medtech (14124)
Mergers & acquisitions (20505)
Metabolic disorders (1462)
mRNA (195)
Multiple sclerosis (180)
NASH (23)
Neurodegenerative disease (401)
Neuropsychiatric disorders (101)
Neuroscience (3274)
Neurotech (1)
NextGen: Class of 2026 (6726)
Non-profit (4695)
Now hiring (75)
Obesity (696)
Opinion (306)
Ovarian cancer (205)
Pain (247)
Pancreatic cancer (274)
Parkinson's disease (355)
Partnered (35)
Patents (569)
Patient recruitment (626)
Peanut (63)
People (61457)
Pharmaceutical (69)
Pharmacy benefit managers (32)
Phase 1 (22199)
Phase 2 (31337)
Phase 3 (23330)
Pipeline (7617)
Policy (325)
Postmarket research (2646)
Preclinical (9675)
Press Release (72)
Prostate cancer (285)
Psychedelics (53)
Radiopharmaceuticals (319)
Rare diseases (1033)
Real estate (6285)
Recruiting (77)
Regulatory (25608)
Reports (70)
Research institute (2572)
Resumes & cover letters (378)
Rett syndrome (34)
RNA editing (20)
RSV (90)
Schizophrenia (173)
Series A (287)
Series B (212)
Service/supplier (13)
Sickle cell disease (112)
Special edition (25)
Spinal muscular atrophy (167)
Sponsored (47)
Startups (3834)
State (2)
Stomach cancer (19)
Supply chain (129)
Tariffs (87)
The Weekly (67)
Vaccines (1111)
Venture capital (105)
Weight loss (453)
Women's health (116)
Worklife (22)
Date
Today (150)
Last 7 days (764)
Last 30 days (2771)
Last 365 days (30915)
2026 (9672)
2025 (30744)
2024 (35936)
2023 (40859)
2022 (51925)
2021 (56498)
2020 (54897)
2019 (47646)
2018 (35936)
2017 (33084)
2016 (32665)
2015 (38767)
2014 (32375)
2013 (27536)
2012 (29798)
2011 (30535)
2010 (29032)
Location
Africa (815)
Alabama (93)
Alaska (7)
Arizona (347)
Arkansas (15)
Asia (41252)
Australia (6796)
California (12684)
Canada (3643)
China (1285)
Colorado (551)
Connecticut (549)
Delaware (381)
Europe (90214)
Florida (1897)
Georgia (416)
Hawaii (4)
Idaho (63)
Illinois (1017)
India (88)
Indiana (591)
Iowa (24)
Japan (516)
Kansas (132)
Kentucky (49)
Louisiana (39)
Maine (75)
Maryland (1527)
Massachusetts (9140)
Michigan (372)
Minnesota (713)
Mississippi (7)
Missouri (144)
Montana (33)
Nebraska (29)
Nevada (140)
New Hampshire (86)
New Jersey (3393)
New Mexico (30)
New York (3362)
North Carolina (1652)
North Dakota (10)
Northern California (6285)
Ohio (380)
Oklahoma (24)
Oregon (42)
Pennsylvania (2563)
Puerto Rico (28)
Rhode Island (50)
South America (1187)
South Carolina (83)
South Dakota (2)
Southern California (4992)
Tennessee (206)
Texas (2028)
United States (45191)
Utah (382)
Vermont (1)
Virginia (303)
Washington D.C. (85)
Washington State (1024)
West Virginia (4)
Wisconsin (137)
Wyoming (2)
750,648 Results for "cassava sciences inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Cassava Sciences Announces Name Change to Filana Therapeutics, Inc.
March 10, 2026
·
5 min read
Press Releases
Cassava Sciences Appoints Dawn C. Bir to the Board of Directors
October 23, 2025
·
6 min read
Press Releases
Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer
August 8, 2025
·
6 min read
Press Releases
Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer’s Disease in the Journal of Prevention of Alzheimer’s Disease
January 13, 2026
·
9 min read
Press Releases
Cassava Sciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
August 25, 2025
·
1 min read
Collaboration
Cassava’s Stock Rises After Licensing Seizure Rights for Embattled Drug Simufilam
The licensing deal follows years of controversy for Cassava, as well as the high-profile late-stage failure of its Alzheimer’s disease drug simufilam.
February 28, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Cassava Reports Q3 2025 Financials Results and Provides Business Update
November 13, 2025
·
13 min read
Press Releases
Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy
August 5, 2025
·
10 min read
Alzheimer’s disease
Cassava Finally Ends Alzheimer’s Program for Embattled Simufilam
After years of controversy and allegations of doctored data, Cassava is moving on from Alzheimer’s.
March 25, 2025
·
1 min read
·
Annalee Armstrong
Alzheimer’s disease
Cassava’s Shares Plunge as Alzheimer’s Drug Fails Phase III
Cassava Sciences has revealed the late-stage clinical failure of controversial Alzheimer’s drug simulfilam. The company had pledged to share the results whether “good, bad or ambiguous.”
November 25, 2024
·
2 min read
·
Annalee Armstrong
1 of 75,065
Next
